EMA Authorised: Redemplo (plozasiran sodium) — Arrowhead Pharmaceuticals Ireland Limited

View source ↗

Summary

EMA has authorised Redemplo (plozasiran sodium) from Arrowhead Pharmaceuticals Ireland Limited for Hyperlipoproteinemia Type I.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipoproteinemia Type

Drugs mentioned

• REDEMPLO (PLOZASIRAN)

Snippet

Status: Authorised. Therapeutic area: Hyperlipoproteinemia Type I. MAH: Arrowhead Pharmaceuticals Ireland Limited. Decision date: 19/06/2026. Orphan medicine